EICHORCondition: Acute Leukemia · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
LThe main aim of this project is to provide an immunophenotypic and immunometabolic characterisation of patients with Acute Leukaemia, before and after therapy, and to understand how changes in the immune system impact the response to therapy. Specifically: 1. The association between the molecular and metabolic characteristics of leukaemic cells and those of the surrounding immune system will be assessed, in order to identify immune-modulatory metabolic mechanisms activated by malignant cells. 2. The association between immunometabolic signatures and response to therapies will be assessed. 3. The role of EVs as a vehicle for metabolic units capable of regulating the metabolism of immune system cells will be explored.
This description comes directly from the study's public registry record.
Antonio Curti, MD · +39 0512144074 · antonio.curti2@unibo.it
Always discuss trial participation with your own doctor first.
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | Bologna, Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06814444